In vivo tumor imaging using polo-box domain of polo-like kinase 1 targeted peptide

Biomaterials

Volumn 33, Issue 29, 2012, Pages 6915-6925

  Kim, Sung Min ^a   Yoon, Sunmi ^a   Choi, Naeun ^a   Hong, Kwan Soo ^a   Murugan, Ravichandran N ^a   Cho, Gyunggoo ^a   Ryu, Eun Kyoung ^a  

^a Korea Basic Science Institute (KBSI)   (South Korea)

Author keywords

CRGDyK S S CPLHSpT; Drug delivery; Molecular imaging; PET; Polo box domain; Polo like kinase 1

Indexed keywords

ANTI-CANCER THERAPIES; ANTICANCER DRUG; APOPTOTIC CELL DEATH; CANCER CELLS; CELL-CYCLE PROGRESSION; CRGDYK-S-S-CPLHSPT; IN-VITRO; IN-VIVO; KINASE ACTIVITY; MITOTIC ARREST; PEPTIDE INHIBITORS; PET IMAGES; PHOSPHOPEPTIDES; POLO-BOX DOMAIN; POLO-LIKE KINASE; RADIOLIGANDS; SELECTIVE INHIBITORS; TUMOR DIAGNOSIS; TUMOR IMAGING;

BUDGET CONTROL; CELL DEATH; DRUG DELIVERY; ENZYMES; MOLECULAR IMAGING; PEPTIDES; POLYETHYLENE TEREPHTHALATES; POSITRON EMISSION TOMOGRAPHY; TUMORS;

DIAGNOSIS;

ANTINEOPLASTIC AGENT; ARGINYLGLYCYLASPARTIC ACID; GALLIUM 68; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHOPEPTIDE; POLO LIKE KINASE 1; PROTEIN SERINE THREONINE KINASE INHIBITOR; RADIOLIGAND; CELL CYCLE PROTEIN; ONCOPROTEIN; PEPTIDE; POLO-LIKE KINASE 1; PROTEIN SERINE THREONINE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CARBOXY TERMINAL SEQUENCE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EFFECT; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; FLUORESCENCE MICROSCOPY; HISTOLOGY; HUMAN; HUMAN CELL; IN VIVO STUDY; INTERNALIZATION; ISOTOPE LABELING; MALE; MITOSIS INHIBITION; MOLECULAR IMAGING; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN DOMAIN; TUMOR DIAGNOSIS; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; CELL SEPARATION; CHEMICAL MODEL; CHEMISTRY; FLOW CYTOMETRY; HELA CELL; METABOLISM; METHODOLOGY; MITOSIS; NEOPLASM; PATHOLOGY; PROTEIN TERTIARY STRUCTURE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SEPARATION; DRUG DELIVERY SYSTEMS; FLOW CYTOMETRY; HELA CELLS; HUMANS; MALE; MICE; MICE, INBRED BALB C; MITOSIS; MODELS, CHEMICAL; NEOPLASM TRANSPLANTATION; NEOPLASMS; PEPTIDES; POSITRON-EMISSION TOMOGRAPHY; PROTEIN STRUCTURE, TERTIARY; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS;

EID: 84864298719     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.06.046     Document Type: Article

References (30)

1. Barr F.A., Sillje H.H., Nigg E.A. Polo-like kinases and the orchestration of cell division. Nat Rev Mol Cell Biol 2004, 5:429-440.
2. Elez R., Piiper A., Giannini C.D., Brendel M., Zeuzem S. Polo-like kinase1, a new target for antisense tumor therapy. Biochem Biophys Res Commun 2000, 269:352-356.
3. Lane H.A., Nigg E.A. Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes. J Cell Biol 1996, 135:1701-1713.
4. Takai N., Hamanaka R., Yoshimatsu J., Miyakawa I. Polo-like kinases (Plks) and cancer. Oncogene 2005, 24:287-291.
5. McInnes C., Mezna M., Fischer P.M. Progress in the discovery of polo-like kinase inhibitors. Curr Top Med Chem 2005, 5:181-197.
6. Spankuch B., Matthess Y., Knecht R., Zimmer B., Kaufmann M., Strebhardt K. Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1. J Natl Cancer Inst 2004, 96:862-872.
7. Elia A.E., Rellos P., Haire L.F., Chao J.W., Ivins F.J., Hoepker K., et al. The molecular basis for phosphodependent substrate targeting and regulation of Plks by the Polo-box domain. Cell 2003, 115:83-95.
8. Garcia-Alvarez B., de Carcer G., Ibanez S., Bragado-Nilsson E., Montoya G. Molecular and structural basis of polo-like kinase 1 substrate recognition: implications in centrosomal localization. Proc Natl Acad Sci U S A 2007, 104:3107-3112.
9. Elez R., Piiper A., Kronenberger B., Kock M., Brendel M., Hermann E., et al. Tumor regression by combination antisense therapy against Plk1 and Bcl-2. Oncogene 2003, 22:69-80.
10. Lansing T.J., McConnell R.T., Duckett D.R., Spehar G.M., Knick V.B., Hassler D.F., et al. In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1. Mol Cancer Ther 2007, 6:450-459.
11. Watanabe N., Sekine T., Takagi M., Iwasaki J., Imamoto N., Kawasaki H., et al. Deficiency in chromosome congression by the inhibition of Plk1 polo box domain-dependent recognition. J Biol Chem 2009, 284:2344-2353.
12. Liu X., Erikson R.L. Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci U S A 2003, 100:5789-5794.
13. Chen X.H., Lan B., Qu Y., Zhang X.Q., Cai Q., Liu B.Y., et al. Inhibitory effect of polo-like kinase 1 depletion on mitosis and apoptosis of gastric cancer cells. World J Gastroenterol 2006, 12:29-35.
14. Guan R., Tapang P., Leverson J.D., Albert D., Giranda V.L., Luo Y. Small interfering RNA-mediated Polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals. Cancer Res 2005, 65:2698-2704.
15. Nogawa M., Yuasa T., Kimura S., Tanaka M., Kuroda J., Sato K., et al. Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer. J Clin Invest 2005, 115:978-985.
16. Liu X., Lei M., Erikson R.L. Normal cells, but not cancer cells, survive severe Plk1 depletion. Mol Cell Biol 2006, 26:2093-2108.
17. Yun S.M., Moulaei T., Lim D., Bang J.K., Park J.E., Shenoy S.R., et al. Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1. Nat Struct Mol Biol 2009, 16:876-882.
18. Brooks P.C., Clark R.A., Cheresh D.A. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994, 264:569-571.
19. Friedlander M., Brooks P.C., Shaffer R.W., Kincaid C.M., Varner J.A., Cheresh D.A. Definition of two angiogenic pathways by distinct alpha v integrins. Science 1995, 270:1500-1502.
20. Kerfoot S.M., Norman M.U., Lapointe B.M., Bonder C.S., Zbytnuik L., Kubes P. Reevaluation of P-selectin and alpha 4 integrin as targets for the treatment of experimental autoimmune encephalomyelitis. J Immunol 2006, 176:6225-6234.
21. Chen X., Park R., Shahinian A.H., Tohme M., Khankaldyyan V., Bozorgzadeh M.H., et al. 18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis. Nucl Med Biol 2004, 31:179-189.
22. Liu S., Hsieh W.Y., Jiang Y., Kim Y.S., Sreerama S.G., Chen X., et al. Evaluation of a (99m) Tc-labeled cyclic RGD tetramer for noninvasive imaging integrin alpha(v)beta3-positive breast cancer. Bioconjug Chem 2007, 18:438-446.
23. Mulder W.J., Strijkers G.J., Habets J.W., Bleeker E.J., van der Schaft D.W., Storm G., et al. MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle. FASEB J 2005, 19:2008-2010.
24. Huang C.W., Li Z., Conti P.S. In vivo near-infrared fluorescence imaging of integrin alpha2beta1 in prostate cancer with cell-penetrating-peptide-conjugated DGEA probe. J Nucl Med 2011, 52:1979-1986.
25. Chen X., Conti P.S., Moats R.A. In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in brain tumor xenografts. Cancer Res 2004, 64:8009-8014.
26. Chen X., Park R., Tohme M., Shahinian A.H., Bading J.R., Conti P.S. MicroPET and autoradiographic imaging of breast cancer alpha v-integrin expression using 18F- and 64Cu-labeled RGD peptide. Bioconjug Chem 2004, 15:41-49.
27. Janssen M.L., Oyen W.J., Dijkgraaf I., Massuger L.F., Frielink C., Edwards D.S., et al. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model. Cancer Res 2002, 62:6146-6151.
28. Saito G., Swanson J.A., Lee K.D. Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities. Adv Drug Deliv Rev 2003, 55:199-215.
29. Falnes P.O., Sandvig K. Penetration of protein toxins into cells. Curr Opin Cell Biol 2000, 12:407-413.
30. Dietzmann K., Kirches E., von B., Jachau K., Mawrin C. Increased human polo-like kinase-1 expression in gliomas. J Neurooncol 2001, 53:1-11.